Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab.

Salvatore Cillino, Maria Vadala', Francesco Boscia, Federico Ricci, Alfredo Pece

Risultato della ricerca: Article

14 Citazioni (Scopus)

Abstract

Abstract PURPOSE: The purpose of this study was to report the visual outcome of intravitreal therapy with ranibizumab of choroidal neovascularization secondary to angioid streaks after 1-year follow-up. METHODS: Nine patients (age, 58 +/- 4 years; range, 53-65 years) were treated with off-label intravitreal injections of 0.3 mg ranibizumab. Primary outcomes were best-corrected visual acuity changes (Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution and letters) and optical coherence tomography macular thickness changes. RESULTS: Mean follow-up was 14 months (+/-2; range, 12-18 months). Mean visual acuity was 0.52 logarithm of the minimum angle of resolution and 30 letters (range, 0.2-1.2; 0-47 letters) at baseline and 0.37 logarithm of the minimum angle of resolution (P = 0.014) and 37 letters (range, 0-1.2; 2-55 letters) (P = 0.01) at the last examination. Seven of 9 patients (78%) gained vision (mean, 2 lines), 1 patient (11 %) was stable, and 1 patient (11 %) lost 1 line of vision (5 letters). Two patients (22%) gained >or=3 lines of visual acuity, no patient lost >1 line. Mean optical coherence tomography macular thickness was 262.4 microm (+/-34.4 standard deviation) at baseline and 216.4 microm (+/-19 standard deviation) at the last examination (P = 0.05). The mean number of injection was 5 (range, 3-7); 78% of patients needed to be retreated after the loading dose of 3 monthly injections.
Lingua originaleEnglish
pagine (da-a)903-907
Numero di pagine5
RivistaRetina
Volume30
Stato di pubblicazionePublished - 2010

Fingerprint

Angioid Streaks
Choroidal Neovascularization
Visual Acuity
Optical Coherence Tomography
Intravitreal Injections
Injections
Diabetic Retinopathy
Ranibizumab

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cita questo

Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab. / Cillino, Salvatore; Vadala', Maria; Boscia, Francesco; Ricci, Federico; Pece, Alfredo.

In: Retina, Vol. 30, 2010, pag. 903-907.

Risultato della ricerca: Article

Cillino, Salvatore ; Vadala', Maria ; Boscia, Francesco ; Ricci, Federico ; Pece, Alfredo. / Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab. In: Retina. 2010 ; Vol. 30. pagg. 903-907.
@article{e4f42739ade1468b90b2f366cad222ae,
title = "Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab.",
abstract = "Abstract PURPOSE: The purpose of this study was to report the visual outcome of intravitreal therapy with ranibizumab of choroidal neovascularization secondary to angioid streaks after 1-year follow-up. METHODS: Nine patients (age, 58 +/- 4 years; range, 53-65 years) were treated with off-label intravitreal injections of 0.3 mg ranibizumab. Primary outcomes were best-corrected visual acuity changes (Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution and letters) and optical coherence tomography macular thickness changes. RESULTS: Mean follow-up was 14 months (+/-2; range, 12-18 months). Mean visual acuity was 0.52 logarithm of the minimum angle of resolution and 30 letters (range, 0.2-1.2; 0-47 letters) at baseline and 0.37 logarithm of the minimum angle of resolution (P = 0.014) and 37 letters (range, 0-1.2; 2-55 letters) (P = 0.01) at the last examination. Seven of 9 patients (78{\%}) gained vision (mean, 2 lines), 1 patient (11 {\%}) was stable, and 1 patient (11 {\%}) lost 1 line of vision (5 letters). Two patients (22{\%}) gained >or=3 lines of visual acuity, no patient lost >1 line. Mean optical coherence tomography macular thickness was 262.4 microm (+/-34.4 standard deviation) at baseline and 216.4 microm (+/-19 standard deviation) at the last examination (P = 0.05). The mean number of injection was 5 (range, 3-7); 78{\%} of patients needed to be retreated after the loading dose of 3 monthly injections.",
author = "Salvatore Cillino and Maria Vadala' and Francesco Boscia and Federico Ricci and Alfredo Pece",
year = "2010",
language = "English",
volume = "30",
pages = "903--907",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab.

AU - Cillino, Salvatore

AU - Vadala', Maria

AU - Boscia, Francesco

AU - Ricci, Federico

AU - Pece, Alfredo

PY - 2010

Y1 - 2010

N2 - Abstract PURPOSE: The purpose of this study was to report the visual outcome of intravitreal therapy with ranibizumab of choroidal neovascularization secondary to angioid streaks after 1-year follow-up. METHODS: Nine patients (age, 58 +/- 4 years; range, 53-65 years) were treated with off-label intravitreal injections of 0.3 mg ranibizumab. Primary outcomes were best-corrected visual acuity changes (Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution and letters) and optical coherence tomography macular thickness changes. RESULTS: Mean follow-up was 14 months (+/-2; range, 12-18 months). Mean visual acuity was 0.52 logarithm of the minimum angle of resolution and 30 letters (range, 0.2-1.2; 0-47 letters) at baseline and 0.37 logarithm of the minimum angle of resolution (P = 0.014) and 37 letters (range, 0-1.2; 2-55 letters) (P = 0.01) at the last examination. Seven of 9 patients (78%) gained vision (mean, 2 lines), 1 patient (11 %) was stable, and 1 patient (11 %) lost 1 line of vision (5 letters). Two patients (22%) gained >or=3 lines of visual acuity, no patient lost >1 line. Mean optical coherence tomography macular thickness was 262.4 microm (+/-34.4 standard deviation) at baseline and 216.4 microm (+/-19 standard deviation) at the last examination (P = 0.05). The mean number of injection was 5 (range, 3-7); 78% of patients needed to be retreated after the loading dose of 3 monthly injections.

AB - Abstract PURPOSE: The purpose of this study was to report the visual outcome of intravitreal therapy with ranibizumab of choroidal neovascularization secondary to angioid streaks after 1-year follow-up. METHODS: Nine patients (age, 58 +/- 4 years; range, 53-65 years) were treated with off-label intravitreal injections of 0.3 mg ranibizumab. Primary outcomes were best-corrected visual acuity changes (Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution and letters) and optical coherence tomography macular thickness changes. RESULTS: Mean follow-up was 14 months (+/-2; range, 12-18 months). Mean visual acuity was 0.52 logarithm of the minimum angle of resolution and 30 letters (range, 0.2-1.2; 0-47 letters) at baseline and 0.37 logarithm of the minimum angle of resolution (P = 0.014) and 37 letters (range, 0-1.2; 2-55 letters) (P = 0.01) at the last examination. Seven of 9 patients (78%) gained vision (mean, 2 lines), 1 patient (11 %) was stable, and 1 patient (11 %) lost 1 line of vision (5 letters). Two patients (22%) gained >or=3 lines of visual acuity, no patient lost >1 line. Mean optical coherence tomography macular thickness was 262.4 microm (+/-34.4 standard deviation) at baseline and 216.4 microm (+/-19 standard deviation) at the last examination (P = 0.05). The mean number of injection was 5 (range, 3-7); 78% of patients needed to be retreated after the loading dose of 3 monthly injections.

UR - http://hdl.handle.net/10447/73191

M3 - Article

VL - 30

SP - 903

EP - 907

JO - Retina

JF - Retina

SN - 0275-004X

ER -